• Je něco špatně v tomto záznamu ?

Amaranth as a potential dietary adjunct of lifestyle modification to improve cardiovascular risk profile

Z. Chmelík, M. Šnejdrlová, M. Vrablík,

. 2019 ; 72 (-) : 36-45. [pub] 20191022

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028739

The aim of this review was to summarize data regarding amaranth as a potential component of lifestyle modification to improve cardiovascular risk profiles by modifying cardiovascular risk factors such as cholesterol, diabetes, and hypertension. PubMed was searched for appropriate articles. The main inclusion criteria for articles were as follows: interventions with amaranth; conducted in humans or animals or in vitro; and reported serum lipids and lipoprotein levels, and antidiabetic, antihypertensive, and antioxidant abilities. The outcome measures were changes in serum lipids and the presence of antidiabetic, antihypertensive, and antioxidant activity. A total of 33 articles were included herein. Regarding hypolipidemic activity, most studies investigated the effect of intervention with amaranth in animals, and fewer studies were performed in humans. Most studies in animal models demonstrated the ability of amaranth to decrease total cholesterol and low-density lipoprotein cholesterol. Pilot studies in humans were not convincing regarding amaranth's lipid-lowering activity. Based on this search, it is not clear which constituents are potentially responsible for the hypocholesterolemic effect of amaranth. Some authors tend to think that squalene can play a role in this effect, whereas others suggest that different components of amaranth are of greater importance (eg, sterols, oil fractions rich in fatty acids, proteins, amino acids, or fiber) for its hypocholesterolemic effect. It is possible that several constituents are jointly responsible for this action. Regarding the antidiabetic, antihypertensive, and antioxidant activities, most studies were performed in vitro and showed good potential for all three biological effects. Future research should focus on clarifying the effect of amaranth on high-density lipoprotein cholesterol, identifying the constituents responsible for these beneficial effects, and providing more data regarding its use in humans, ideally using randomized controlled trials. The antidiabetic, antihypertensive, and antioxidant activities found in vitro should be confirmed further in animal or human models.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028739
003      
CZ-PrNML
005      
20210114154928.0
007      
ta
008      
210105s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.nutres.2019.09.006 $2 doi
035    __
$a (PubMed)31757630
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chmelík, Zdeněk $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University and General Faculty Hospital in Prague, U Nemocnice 1, 128 08, Prague 2, Czech Republic. Electronic address: chmelik.zdenek@gmail.com.
245    10
$a Amaranth as a potential dietary adjunct of lifestyle modification to improve cardiovascular risk profile / $c Z. Chmelík, M. Šnejdrlová, M. Vrablík,
520    9_
$a The aim of this review was to summarize data regarding amaranth as a potential component of lifestyle modification to improve cardiovascular risk profiles by modifying cardiovascular risk factors such as cholesterol, diabetes, and hypertension. PubMed was searched for appropriate articles. The main inclusion criteria for articles were as follows: interventions with amaranth; conducted in humans or animals or in vitro; and reported serum lipids and lipoprotein levels, and antidiabetic, antihypertensive, and antioxidant abilities. The outcome measures were changes in serum lipids and the presence of antidiabetic, antihypertensive, and antioxidant activity. A total of 33 articles were included herein. Regarding hypolipidemic activity, most studies investigated the effect of intervention with amaranth in animals, and fewer studies were performed in humans. Most studies in animal models demonstrated the ability of amaranth to decrease total cholesterol and low-density lipoprotein cholesterol. Pilot studies in humans were not convincing regarding amaranth's lipid-lowering activity. Based on this search, it is not clear which constituents are potentially responsible for the hypocholesterolemic effect of amaranth. Some authors tend to think that squalene can play a role in this effect, whereas others suggest that different components of amaranth are of greater importance (eg, sterols, oil fractions rich in fatty acids, proteins, amino acids, or fiber) for its hypocholesterolemic effect. It is possible that several constituents are jointly responsible for this action. Regarding the antidiabetic, antihypertensive, and antioxidant activities, most studies were performed in vitro and showed good potential for all three biological effects. Future research should focus on clarifying the effect of amaranth on high-density lipoprotein cholesterol, identifying the constituents responsible for these beneficial effects, and providing more data regarding its use in humans, ideally using randomized controlled trials. The antidiabetic, antihypertensive, and antioxidant activities found in vitro should be confirmed further in animal or human models.
650    _2
$a amarant $x metabolismus $7 D027721
650    _2
$a zvířata $7 D000818
650    _2
$a kardiovaskulární nemoci $x metabolismus $x prevence a kontrola $7 D002318
650    _2
$a cholesterol $x krev $7 D002784
650    _2
$a dieta $x metody $7 D004032
650    _2
$a jedlá semena $x metabolismus $7 D002523
650    _2
$a lidé $7 D006801
650    12
$a životní styl $7 D008019
650    _2
$a lipidy $x krev $7 D008055
650    _2
$a riziko $7 D012306
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Šnejdrlová, Michaela $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University and General Faculty Hospital in Prague, U Nemocnice 1, 128 08, Prague 2, Czech Republic. Electronic address: Mmichaela.snejdrlova@1lf.cuni.cz.
700    1_
$a Vrablík, Michal $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University and General Faculty Hospital in Prague, U Nemocnice 1, 128 08, Prague 2, Czech Republic. Electronic address: michal.vrablik@lf1.cuni.cz.
773    0_
$w MED00008649 $t Nutrition research (New York, N.Y.) $x 1879-0739 $g Roč. 72, č. - (2019), s. 36-45
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31757630 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154925 $b ABA008
999    __
$a ok $b bmc $g 1609074 $s 1119919
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 72 $c - $d 36-45 $e 20191022 $i 1879-0739 $m Nutrition research $n Nutr Res $x MED00008649
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...